Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

Ocrevus

5 posts
RRoche
#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
Read More

#AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring

  • 2026-04-22
Roche’s mul­ti­ple scle­ro­sis pill more than dou­bled pa­tients’ re­lapse-free in­ter­val com­pared with Sanofi’s mar­ket­ed MS pill Auba­gio, ac­cord­ing…
RRoche
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Read More

Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?

  • 2026-02-18
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of…
RRoche
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Read More

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

  • 2026-02-17
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial

  • 2026-02-17
Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…
RRoche
Roche fenebrutinib Phase III hits PPMS disability goal
Read More

Roche fenebrutinib Phase III hits PPMS disability goal

  • 2026-02-11
Roche (OTCQX: RHHBY) reported Phase III FENtrepid results showing investigational oral BTK inhibitor…
Switzerland
www.europesays.com